adjust expect recoveri
edward report rev line consensu ahead
recent revis estim biggest surpris quarterli number
tavr revenu y/i ahead consensus/our estim
respect guidanc lower
bracket consensus/our estim
respect impact seen sever gradual recoveri
close ew origin expect tweak estim
slightli reflect compani guidanc maintain fundament posit stanc
name howev edward strong perform stark departur
med-tech compani space ask
us tavr us tavr growth y/i impli revenu came
ultra constitut unit sale math suggest cases/day
unit vs asp impact ultra price premium delta unit
shipment implant pull-through
ou tavr ou growth y/i field check corevalv paint
encourag trend rel would impli edward
suddenli gain quit bit share europ unclear share gain
suddenli occur math suggest cases/day q/q assum
unit get implant sequenti uptick
litig litig pascal continu ew reiter confid
ip compani tone remain unconcern call matter lot countri
date nois believ final decis hing mean leaflet
attach togeth appeal process could drag long time
uncertainti outlook impli guidanc suggest revenu
unclear us reconcil cdc commentari second covid wave
edward outlook potenti hospit shift low-risk ssa savr
financi devast caus covid sinc savr profit
hospit tavr data might chang mind
y/i tavr growth y/i vs prior y/i
surgic growth y/i vs prior y/i critic care growth
y/i vs prior y/i compani commentari impli rel
import updat pascal forthcom next month
year price histori ew
edward lifesci base ca
world leader heart valv therapi
analyst certif import disclosur see disclosur
compound-annual-growth-rate tavr
edward win mitraclip litig non-infring
pascal deliv better outcom mitraclip
tavr usag expand asymptomat sever aortic stenosi
edward lead player tavr space best-
in-class technolog tavr see growth
compound-annual-growth-rate next year believ tmtt transcathet
mitral repres big call option stori edward
excel profil strong revenu ebit margin
ep compound-annual-growth-rate strong strateg manag team round
pictur
clasp pilot studi data patient
edward prohibit sell pascal
util sum-of-the-part methodolog valu edward pt admittedli premium attribut multipl
herewith target market opportun edward strateg play space strength manag team use
multipl tavr sale multipl tmtt sale multipl critic sale
multipl surgic heart valv sale
earli stage us launch tavr space view boston lotu valv go gain
much share threaten edward domin prudent factor share loss extent refin lotu valv
allow easier deliveri discount heavili price execut risk edward increas
current three key player tavr side howev player tmtt side vy piec pie
given early-stag natur space abbott current domin mitral side given competit intens
edward tri enter tmtt space beyond
stori market risk need factor
statement oper
number mm round
good sold
chang fv cont liab
sg
